Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  brain tumor
Stage/Subtype:  brain tumor
Trial Type:  Treatment
Treatment/Intervention:  vaccine therapy
Trial Status:  Active
Results 1-25 of 29 for your search:
Start Over
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Pharmaceutical / Industry
Protocol IDs: 020221, NCT00045968
Dendritic Cell (DC) Activated Cytokine-induced Killer Cell (DCIK) Combined With DC Treatment for Glioma
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 to 70
Sponsor: Other
Protocol IDs: DCCIK001, NCT01235845
Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: Re-MATCH, W81XWH-10-1-0089, CDMRP-PRO93877, NCT01326104
Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: IMA950 Poly ICLC, NCT01920191
Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 2 to 21
Sponsor: Other
Protocol IDs: 14.0855, NCT02332889
Dendritic Cell Cancer Vaccine for High-grade Glioma
Phase: Phase II
Type: Treatment
Status: Active
Age: 3 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: GBM-Vax, NCT01213407
Study of DC Vaccination Against Glioblastoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: DC81001115, NCT01567202
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: A071101, U10CA031946, NCI-2013-00444, NCT01814813
ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ERC1671-H02, UCI 13-14, 2013-9863, NCT01903330
A Vaccine Trial for Low Grade Gliomas
Phase: Phase II
Type: Treatment
Status: Active
Age: 12 months to less than 22 years
Sponsor: Other
Protocol IDs: PRO1310086, NCT02358187
DC Migration Study for Newly-Diagnosed GBM
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: Pro00054740, NCT02366728
Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia
Phase: Phase I
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: Pro00000581, P50CA108786, P30CA014236, SPORE Project 3, CDR0000579683, DUMC-PRO00000581, NCT00626483
Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 06-349, NCT00694330
Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma
Phase: Phase I
Type: Treatment
Status: Active
Age: 3 and over
Sponsor: Other
Protocol IDs: 2009LS136, 1004M81213, NCT01400672
Derivation of Tumor Specific Hybridomas
Phase: Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: W12209, NCT01702792
Dendritic Cell Vaccine For Malignant Glioma and Glioblastoma Multiforme in Adult and Pediatric Subjects
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 13 to 99
Sponsor: Other
Protocol IDs: 20120750, NCT01808820
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
Phase: Phase I
Type: Treatment
Status: Active
Age: Over 1 year to less than 30 years
Sponsor: Other
Protocol IDs: 20130136, NCT01902771
Phase I Study of Safety and Immunogenicity of ADU-623
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 13-012A, NCT01967758
Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 33203, NCT02010606
A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ICT-121 DC-01, NCT02049489
Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: CS-TT-G-01, NCT02122822
GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GAPVAC-101, 2013-002801-71, NCT02149225
RESIST: Patients With IDH1 Positive Recurrent Grade II Glioma Enrolled in a Safety and Immunogenicity Study of Tumor-Specific Peptide Vaccine
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: Pro00054746, NCT02193347
MVX-ONCO-1 in Patients With Solid Tumor
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MVX-2011-01, NCT02193503
Ph I Personalized NeoAntigen Cancer Vaccine With Radiotherapy for Patients With MGMT Unmethylated, Newly Diagnosed Glioblastoma
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 14-362, NCT02287428
Start Over